These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 2201041

  • 1. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M, Serretta V, Daricello G, Pavone C, Cacciatore M, Romano C, Cavallo N.
    Prog Clin Biol Res; 1990; 350():149-57. PubMed ID: 2201041
    [Abstract] [Full Text] [Related]

  • 2. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M, Serretta V, Pavone C, Romano C, Daricello G.
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 4. Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
    Pavone-Macaluso M, Cacciatore M, Daricello G, Pavone C, Serretta V.
    Ann N Y Acad Sci; 1990; 595():328-33. PubMed ID: 2375611
    [Abstract] [Full Text] [Related]

  • 5. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH.
    Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [Abstract] [Full Text] [Related]

  • 6. [Hormone therapy in prostate cancer: clinical results].
    Morote-Robles J.
    Rev Esp Fisiol; 1990 Mar; 46(1):59-62. PubMed ID: 1697693
    [Abstract] [Full Text] [Related]

  • 7. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G, Kolvenbag G, Nash A.
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [Abstract] [Full Text] [Related]

  • 8. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R, Lachance R, Dupont A, Labrie F.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [Abstract] [Full Text] [Related]

  • 9. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA, Sartor O.
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract] [Full Text] [Related]

  • 10. Are organ preservation and maintenance of sexual function compatible with optimal management of prostate cancer? Part 2--Advanced cancer.
    Pavone-Macaluso M.
    Prog Clin Biol Res; 1991 Mar; 370():203-5. PubMed ID: 1924452
    [No Abstract] [Full Text] [Related]

  • 11. Total androgen ablation: American experience.
    Crawford ED, Nabors WL.
    Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
    [Abstract] [Full Text] [Related]

  • 12. Hormone therapy of prostatic bone metastases.
    Huben RP.
    Adv Exp Med Biol; 1992 Feb; 324():305-16. PubMed ID: 1492625
    [Abstract] [Full Text] [Related]

  • 13. Advances in the treatment of metastatic prostatic cancer.
    Elder JS, Gibbons RP.
    West J Med; 1985 Sep; 143(3):342-5. PubMed ID: 2413632
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
    Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J.
    Prog Clin Biol Res; 1989 Sep; 303():161-7. PubMed ID: 2674982
    [No Abstract] [Full Text] [Related]

  • 15. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C, Farkas A, Spitz IM.
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [Abstract] [Full Text] [Related]

  • 16. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 17. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F, Pace M.
    In Vivo; 1993 Aug; 7(5):423-4. PubMed ID: 8110985
    [Abstract] [Full Text] [Related]

  • 18. Principles of endocrine manipulation in the treatment of prostatic cancer.
    Neumann F.
    Prog Clin Biol Res; 1985 Aug; 185A():73-98. PubMed ID: 3898136
    [No Abstract] [Full Text] [Related]

  • 19. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J, Fischer M.
    Wien Klin Wochenschr; 1988 Sep 09; 100(17):589-92. PubMed ID: 3055689
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct 09; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.